New data at ACR meeting show efficacy of Simponi® in active non-radiographic Axial Spondyloarthritis

MSD announced findings from the GO-AHEAD study (1) showing that patients with active non-radiographic axial spondyloarthritis (nr-AxSpA) treated with injections of Simponi® (golimumab) 50 mg every 4 weeks for 16 weeks had significantly greater improvements in disease activity and inflammation on magnetic resonance imaging (MRI) than patients treated with placebo.
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: Tags: *** Editor's Pick Practical therapeutics Industry News Rheumatology Patient care GO-AHEAD study golimumab Latest News non-radiographic axial spondyloarthritis Simponi Source Type: news